LLY

1,043.77

+0.35%↑

JNJ

243.66

-0.28%↓

ABBV

232.22

+3.02%↑

NVS

162.26

+0.56%↑

MRK

121.54

+0.79%↑

LLY

1,043.77

+0.35%↑

JNJ

243.66

-0.28%↓

ABBV

232.22

+3.02%↑

NVS

162.26

+0.56%↑

MRK

121.54

+0.79%↑

LLY

1,043.77

+0.35%↑

JNJ

243.66

-0.28%↓

ABBV

232.22

+3.02%↑

NVS

162.26

+0.56%↑

MRK

121.54

+0.79%↑

LLY

1,043.77

+0.35%↑

JNJ

243.66

-0.28%↓

ABBV

232.22

+3.02%↑

NVS

162.26

+0.56%↑

MRK

121.54

+0.79%↑

LLY

1,043.77

+0.35%↑

JNJ

243.66

-0.28%↓

ABBV

232.22

+3.02%↑

NVS

162.26

+0.56%↑

MRK

121.54

+0.79%↑

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

21.14 -1.17

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.71

Максимум

21.35

Ключови измерители
By Trading Economics
Приходи	11M -61M
Продажби	7.9M 46M
Марж на печалбата	-132.36
Служители	270
EBITDA	6.3M -58M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+87.21% upside

Дивиденти
By Dow Jones
Следващи печалби	2.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	712M 1.8B
Предишно отваряне	22.31
Предишно затваряне	21.14

Настроения в новините

By Acuity

78%

22%

332 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.02.2026 г., 23:57 ч. UTC

Горещи акции

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12.02.2026 г., 23:35 ч. UTC

Печалби

Значими двигатели на пазара

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12.02.2026 г., 23:28 ч. UTC

Печалби

Applied Materials Profit Rises on Soaring AI Demand -- Update

12.02.2026 г., 21:47 ч. UTC

Печалби

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13.02.2026 г., 00:00 ч. UTC

Пазарно говорене

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12.02.2026 г., 23:38 ч. UTC

Пазарно говорене

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12.02.2026 г., 23:33 ч. UTC

Печалби

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12.02.2026 г., 23:09 ч. UTC

Пазарно говорене

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12.02.2026 г., 22:55 ч. UTC

Печалби

Горещи акции

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12.02.2026 г., 22:46 ч. UTC

Пазарно говорене

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12.02.2026 г., 22:23 ч. UTC

Печалби

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12.02.2026 г., 22:15 ч. UTC

Печалби

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12.02.2026 г., 22:15 ч. UTC

Печалби

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12.02.2026 г., 22:15 ч. UTC

Печалби

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12.02.2026 г., 22:15 ч. UTC

Печалби

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12.02.2026 г., 22:00 ч. UTC

Печалби

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12.02.2026 г., 22:00 ч. UTC

Печалби

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12.02.2026 г., 22:00 ч. UTC

Печалби

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12.02.2026 г., 22:00 ч. UTC

Печалби

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12.02.2026 г., 22:00 ч. UTC

Печалби

12.02.2026 г., 22:00 ч. UTC

Печалби

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12.02.2026 г., 21:57 ч. UTC

Печалби

XP 4Q Rev BRL4.95B >XP

12.02.2026 г., 21:52 ч. UTC

Печалби

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

12.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

12.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.02.2026 г., 21:47 ч. UTC

Печалби

Morningstar 4Q Rev $641M >MORN

12.02.2026 г., 21:39 ч. UTC

Печалби

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12.02.2026 г., 21:38 ч. UTC

Печалби

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

87.21% нагоре

12-месечна прогноза

Среден 39.67 USD 87.21%

Висок 56 USD

Нисък 28 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

332 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.